Skip to main content

Table 5 Cardiac function variables

From: Adenosine, lidocaine and Mg2+improves cardiac and pulmonary function, induces reversible hypotension and exerts anti-inflammatory effects in an endotoxemic porcine model

 

Baseline

60 minutes

90 minutes

120 minutes

150 minutes

180 minutes

210 minutes

240 minutes

270 minutes

300 minutes

EEs slope (mmHg/ml)

          

 Control

1.01 (0.82 to 1.24)

0.88 (0.71 to 1.08)

0.69 (0.56 to 0.85)

0.64 (0.52 to 0.79)

0.73 (0.59 to 0.90)

0.72 (0.58 to 0.88)

0.81 (0.66 to 0.99)

0.89 (0.72 to 1.09)

0.94 (0.77 to 1.16)

0.88 (0.71 to 1.08)

 ALM

0.86 (0.7 to 1.06)

1.05 (0.82 to 1.34)

0.79 (0.64 to 0.97)

0.79 (0.65 to 0.98)

0.81 (0.66 to 1.00)

0.74 (0.60 to 0.91)

0.78 (0.63 to 0.95)

0.73 (0.60 to 0.90)

0.82 (0.67 to 1.01)

0.89 (0.72 to 1.10)

EEs V0 (ml)

          

 Control

–38 (–56 to –20)

–40 (–58 to –22)

–64 (–82 to –45)

–63 (–81 to –45)

–51 (–69 to –32)

–47 (–65 to –28)

–25 (–43 to –7)

–10 (–28 to 9)

–5 (–23 to 13)

0 (–18 to 18)

 ALMa

–48 (–66 to –30)

–7 (–29 to 14)

–25 (–43 to –7)

–26 (–45 to –8)

–29 (–47 to –11)

–31 (–49 to –13)

–23 (–41 to –5)

–30 (–48 to –12)

–39 (–57 to –21)

–33b (–51 to –14)

PRSW slope (mmHg.ml/ml)

          

 Control

70 (58 to 84)

50 (41 to 60)

51 (42 to 61)

42 (35 to 51)

43 (36 to 52)

38 (32 to 46)

40 (33 to 48)

33 (27 to 39)

34 (28 to 41)

36 (30 to 43)

 ALMa

70 (59 to 85)

72 (59 to 88)

64 (54 to 77)

61 (51 to 74)

57 (48 to 69)

56 (46 to 67)

48 (40 to 57)

58 (48 to 70)

66 (54 to 79)

61b (51 to 74)

PRSW V0 (ml)

          

 Control

33 (22 to 44)

24 (13 to 34)

26 (15 to 37)

10 (–1 to 21)

23 (12 to 34)

25 (14 to 35)

45 (34 to 56)

41 (30 to 52)

51 (40 to 61)

51 (40 to 61)

 ALMa

27 (16 to 38)

43 (31 to 56)

46 (35 to 57)

43 (32 to 53)

38 (27 to 48)

41 (30 to 52)

43 (32 to 54)

52 (41 to 62)

37c (26 to 48)

45 (34 to 56)

Tau (milliseconds)

          

 Control

32 (29 to 35)

30 (28 to 33)

35 (32 to 38)

35 (32 to 38)

37 (34 to 40)

38 (35 to 42)

41 (38 to 45)

44 (40 to 48)

44 (41 to 48)

44 (40 to 48)

 ALMa

31 (28 to 34)

33 (30 to 36)

31 (28 to 34)

30 (28 to 33)

32 (29 to 35)

33 (30 to 36)

35 (32 to 38)

36 (33 to 39)

37 (34 to 40)

36b (33 to 39)

Aortic elastance (mmHg/ml)

          

 Control

1.3 (1.1 to 1.5)

1.3 (1.1 to 1.5)

1.2 (1.0 to 1.3)

1.2 (1.1 to 1.4)

1.5 (1.3 to 1.7)

1.6 (1.4 to 1.9)

1.9 (1.7 to 2.2)

2.1 (1.8 to 2.4)

2.2 (1.9 to 2.5)

1.9 (1.7 to 2.2)

 ALMa

1.2 (1.1 to 1.4)

0.9 (0.8 to 1.0)

0.8 (0.7 to 1.0)

0.9 (0.8 to 1.0)

0.9 (0.8 to 1.0)

0.9 (0.8 to 1.1)

1.1 (0.9 to 1.2)

1.1 (0.9 to 1.2)

1.6c (1.4 to 1.9)

1.5b (1.3 to 1.8)

  1. Data presented as median (95% confidence interval), except for Ees V0 and PRSW V0 which are presented as mean (95% confidence interval). ALM, adenosine, lidocaine and magnesium; Ees, end systolic elastance; PRSW, preload recruitable stroke work; V0, volume axis intercept. aSignificantly different change over time between groups. bSignificant difference at the end of the study. cSignificant difference before/after cessation ALM infusion.
Back to article page

Critical Care

ISSN: 1364-8535